Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 nCoV-19 vaccine study in adults in Kenya
PACTR202005681895696Phase 1Recruiting
- Sponsor
- University of Oxford
- Start
- Oct 2020
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Oxford. Primary endpoints: Occurrence of serious adverse events, Solicited local and systemic reactogenicity and 4 more. Started Oct 2020; status: recruiting.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202005681895696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202005681895696.